This post is from a suggested group
Mitigating Side Effects and Improving Patient Quality of Life: A Review of Therapeutic Advancements and Clinical Applications in the Antiemetics Market
The Antiemetics Market is a crucial segment of the pharmaceutical industry, driven primarily by the high incidence of chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and the prevalence of various gastrointestinal disorders and motion sickness. Antiemetic drugs, which target different neurochemical pathways responsible for triggering the vomiting reflex, are essential for improving patient adherence to primary therapies and significantly enhancing the quality of life. The market is dominated by several drug classes, including 5-HT3 receptor antagonists, dopamine antagonists, neurokin-1 (NK-1) receptor antagonists, and corticosteroids, with combination therapy becoming the standard of care for highly emetogenic procedures like aggressive chemotherapy. The emergence of highly effective NK-1 receptor antagonists, offering long-acting formulations, represents a significant therapeutic advancement, particularly in controlling delayed CINV. Furthermore, the growing number of surgical…
